Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#3756 The clinical utility of NETest in patients with small intestinal neuroendocrine neoplasms (SI-NENs) – A "real-life" study

Introduction: Management of patients with SI-NENs is challenging due to biological heterogeneity. Prognostication can be difficult, mostly due to a lack of reliable biomarkers.

Conference:

Presenting Author:

Authors: Gertner J, Hayes A, Furtado O'Mahony L, Glover T, Karia P,

Keywords: Neuroendocrine neoplasm, small intestine, NETest, tumor growth rate, biomarker,

#3021 Homecare Service for Administration of Lanreotide Autogel Injections: Assessment of Patients’ Experience

Introduction: In the past, all Neuroendocrine Neoplasm (NEN) patients (pts) on long-acting somatostatin analogues (SA), had to attend local hospitals/clinics to have them administered by nurses/doctors. Recently, a “homecare service” was developed, allowing pts to have their injections delivered to their home and injections were either administered by themselves, their partner or a Specialist Nurse (SN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Gertner J

Authors: Gertner J, McSweeney A, Furtado O'Mahony L, Quaglia E, John A,

Keywords: homecare,

#3019 Incomplete Peptide Receptor Radionuclide Therapy Courses - Are We Selecting Our Patients Appropriately?

Introduction: As per recommendations, a Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 DOTATATE course usually consists of 4 cycles. Patients may discontinue a PRRT course early, either due to progression or toxicity. Limited data are available about predictive factors for PRRT early discontinuation.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Julian G

Authors: Gertner J, Groves J, Aziz B, Miah L, Furtado O'Mahony L,

Keywords: prrt,

#3018 Real-Life Data for Telotristat Ethyl in Resistant-to-Treatment Carcinoid Syndrome: Is It Efficacious in Carcinoid Flushing as Well?

Introduction: Results from clinical trials with telotristat ethyl (TE) are really encouraging about its role in carcinoid syndrome-associated diarrhoea, however, its efficacy in flushing has been equivocal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Gertner J

Authors: Gertner J, Eastwood O, Furtado O'Mahony L, Quaglia E, McSweeney A,

Keywords: telotristat,

#1106 Salvage Treatment with Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Advanced VIPomas and Severe Verner-Morrison Syndrome

Introduction: PRRT is an effective treatment option for advanced Neuroendocrine Tumours

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Yalchin M, Gertner J, Navalkissoor S, Quigley A, Meyer T,

Keywords: PRRT VIP,